Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 15, 2021 07:00 ET | Source: Trevena Inc.

Trevena Reports Third Quarter 2021 Results

-- Advanced OLINVYK commercial launch with expanded field medical team and additional target markets Announced new OLINVYK cognitive function study vs. IV morphine, enrollment expected...
September 09, 2021 07:00 ET | Source: Trevena Inc.

Trevena to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

CHESTERBROOK, Pa., Sept. 09, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with...
August 12, 2021 07:00 ET | Source: Trevena Inc.

Trevena Reports Second Quarter 2021 Results

Company reaffirms YE goal of 100 formulary wins OLINVYK respiratory physiology study currently enrolling, topline data expected by YE 2021 NIH / Vanderbilt University Medical Center-led...
May 06, 2021 07:00 ET | Source: Trevena Inc.

Trevena Reports First Quarter 2021 Results

-- Company reaffirms YE target of 100 formulary approvals for OLINVYK® Announces new OLINVYK clinical outcomes study to further examine potential benefit on respiratory, GI, and...
January 06, 2021 07:00 ET | Source: Trevena Inc.

Trevena, Inc. Provides Update on Commercial Launch Activities for OLINVYK™ and Announces Anticipated Pipeline Catalysts

-- Build-out of customer-facing team on track for this quarter OLINVYK comprehensive product dossier / health economic model now available to facilitate formulary reviews -- CHESTERBROOK, Pa.,...
December 10, 2020 08:43 ET | Source: Trevena Inc.

Trevena, Inc. Announces Presentations Highlighting Novel S1P1 Receptor Modulator at the American College of Neuropsychopharmacology 59th Annual Meeting

-- Presentations highlight efficacy of TRV045 in animal models of neuropathic pain and epilepsy TRV045 selectively targets the S1P1 receptor without associated lymphopenia IND filing on track for...
May 07, 2020 07:00 ET | Source: Trevena Inc.

Trevena Reports First Quarter 2020 Results

Trevena Reports First Quarter 2020 ResultsFDA review of oliceridine NDA ongoing; PDUFA date August 7, 2020 IND filing for novel S1P modulator (TRV045) in 1H 2021; ongoing collaboration with NIH to...